Teplizumab is believed to reset the immune system, leading to delay or prevention of T1D. In T1D, T cells are triggered to attack β cells. Tregs act as gatekeepers of immunological tolerance.1
1. Long SA, Thorpe J, Herold KC, et al. Remodeling T cell compartments during anti-CD3 immunotherapy of T1D. Cell Immunol. 2017;319:3-9.